RS Research

Description

RS Research develops targeted oncology therapies and smart nanomedicines using the Sagitta® polymer-drug conjugate platform for targeted chemotherapy and theranostics for clinical and investigational oncology programs.

RS Research is located in the Istanbul ecosystem.

Related

• NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…
• Tessellate BioTessellate Bio discovers and develops precision oncology small-molecule medicines based on novel synthetic lethality interactions,…
• Rab DiagnosticsRab Diagnostics develops biomarker tools, assays and the RabCANCER platform to predict antibody–drug conjugate response for pharma…
• BiodiatechBiodiatech offers metabolomic diagnosis and therapy monitoring through targeted and untargeted assays, HRUS imaging in small animals, and…
• ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
• Trained Therapeutix DiscoveryTrained Therapeutix Discovery develops nanobiologic therapeutics that regulate trained immunity for applications in cancer and organ…
• MedisoMediso develops and manufactures clinical and pre-clinical nuclear and hybrid imaging systems, including AnyScan SPECT/CT/PET platforms and…
• BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
• Captor TherapeuticsCaptor Therapeutics develops therapeutics using targeted protein degradation (TPD) to address high‑unmet‑need diseases such as cancer and…